Main > A1. CORP. INDEX. T-Tm > Terumo/P C2 > Terumo Cardiovascular/P C2 > 2018. 11.14. USA 510(k) Clearance

---

for the CDIŽ Blood Parameter Monitoring System 550, Adding New Parameter for Oxygen Delivery

ANN ARBOR, Mich., /PRNewswire/ --Terumo Cardiovascular Group, a global leader in cardiovascular surgery technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the CDIŽ Blood Parameter Monitoring System 550, adding real-time monitoring of oxygen delivery as one of 12 critical blood parameters.

Oxygen delivery, or DO2, is an indicator of the amount of oxygen being delivered to a patient during cardiopulmonary bypass. Carefully monitoring DO2 has been shown to help reduce the incidence of Acute Kidney Injury, a common complication of cardiac surgery.1


2018. 11.14. USA 510(k) Clearance's products
This section has no products